Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase 1B Study of NEO-PV-01 With Pembrolizumab Plus Chemotherapy in Patients With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

NCT03380871 is registered in ClinicalTrials.gov with BioNTech US Inc. as lead sponsor.

NCT NCT03380871
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03380871 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase 1B Study of NEO-PV-01 With Pembrolizumab Plus Chemotherapy in Patients With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer
Lead sponsor
BioNTech US Inc.
Phase
Phase 1
Overall status
Completed
Start date
May 4, 2018
Completion date
February 5, 2021
Enrollment
38 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung, lung cancer, nonsquamous nonsmall cell neoplasm of lung